A Canadian team presented data on this topic at the American Society of Clinical Oncology meeting at Chicago.
The team says it can be safely done in select group of patients without compromising the survival.
Delayed treatment without putting patients through nasty side effects is certainly a welcome option for some patients.
Reference
1. ASCO 2019: Abstract number 4516.
Session: Genitourinary (Nonprostate) Cancer. Type: Poster Discussion Session
